fda tirzepatide shortage says the weight-loss drug is over Eli Lilly's tirzepatide is off

Long-Acting Formulation: Some versions of semaglutide are designed to provide sustained effects with weekly injections, reducing the need for frequent dosing and making it more convenient for patients.

Could Lilly be the first $1 trillion biopharma stock? Morgan Stanley analyst Terence Flynn and the team questioned, adding, We continue to see a path for further upside. With an Overweight rating (no pun intended) on LLY, Morgan Stanley increased its price target on the stock from $805 to $950, which, according to Bloomberg, is the highest on Wall Street and implies about a $900B market cap

Physiological Reports

doi: 10.2174/1389201021666200305115101